Storia in 4 fonti

Roivant’s road to a potential blockbuster begins with Lisraya FDA approval

FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across indications.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo2 g fa

Roivant’s road to a potential blockbuster begins with Lisraya FDA approval

FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across indications.

originale

biopharmadive.com2 g fa

FDA green lights Priovant drug for rare skin disease

Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.

Leggi questa versione → originale

Timeline cronologica

giovedì 27 agosto 2026·statnews.com
FDA approves Roivant therapy for rare autoimmune disease
The FDA approved a new medicine from Roivant and its subsidiary Priovant for the treatment of dermatomyositis, a rare autoimmune disease.
giovedì 27 agosto 2026·endpoints.news
Roivant’s road to a potential blockbuster begins with Lisraya FDA approval
FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across indications.

Roivant’s road to a potential blockbuster begins with Lisraya FDA approval

Confronto fonti

Roivant’s road to a potential blockbuster begins with Lisraya FDA approval

FDA green lights Priovant drug for rare skin disease

Timeline cronologica

FDA approves Roivant therapy for rare autoimmune disease

Roivant’s road to a potential blockbuster begins with Lisraya FDA approval

FDA approves Lisraya as first oral drug for dermatomyositis

FDA approves Roivant therapy for rare autoimmune disease

FDA green lights Priovant drug for rare skin disease

FDA approves Lisraya as first oral drug for dermatomyositis